Fellowship · New Brunswick, NJ
Sponsored by Rutgers Health
Expert consensus on the management of systemic sclerosis-associated interstitial lung disease.
Respiratory research · 2023 · 105 citations · Vivien Hsu
Tocilizumab Prevents Progression of Early Systemic Sclerosis-Associated Interstitial Lung Disease.
Arthritis & rheumatology (Hoboken, N.J.) · 2021 · 148 citations · David Roofeh
Systemic Sclerosis-Associated Interstitial Lung Disease: How to Incorporate Two Food and Drug Administration-Approved Therapies in Clinical Practice.
Arthritis & rheumatology (Hoboken, N.J.) · 2022 · 93 citations · David Roofeh
Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic Sclerosis.
Arthritis & rheumatology (Hoboken, N.J.) · 2023 · 37 citations · Vivien Hsu
Clinical characteristics, visceral involvement, and mortality in at-risk or early diffuse systemic sclerosis: a longitudinal analysis of an observational prospective multicenter US cohort.
Arthritis research & therapy · 2021 · 56 citations · David Roofeh
Therapeutic Approaches to Systemic Sclerosis: Recent Approvals and Future Candidate Therapies.
Clinical reviews in allergy & immunology · 2023 · 34 citations ·
Risk factors for lung function decline in systemic sclerosis-associated interstitial lung disease in a large single-centre cohort.
Rheumatology (Oxford, England) · 2023 · 26 citations · David Roofeh
A comprehensive framework for navigating patient care in systemic sclerosis: A global response to the need for improving the practice of diagnostic and preventive strategies in SSc.
Best practice & research. Clinical rheumatology · 2021 · 34 citations · Vivien Hsu